GlassScriptPhysician profile
Khaled A Osman
NPI 1518131846
$4,716.61
in general payments reported to CMS, 2019-2025
32 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what 95% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.04 · 2020: $101 · 2021: $219 · 2022: $155 · 2023: $1,269 · 2024: $1,387 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,056 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,055.83 |
| Education | $110.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $487.50 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $391.46 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $371.20 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $338.15 | 2022-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $325.48 | 2021-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $290.43 | 2024-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $256.72 | 2019-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $254.70 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Ardelyx, INC. | $215.34 | 2024-2025 | Ibsrela |
| Pfizer INC. | $206.49 | 2022-2025 | |
| Exact Sciences Corporation | $184.00 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $177.74 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $173.36 | 2024-2025 | Voquezna |
| Optinose US, INC. | $164.10 | 2021-2025 | |
| Shield Therapeutics INC | $124.91 | 2023-2024 | Accrufer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $121.39 | 2024-2025 | Gvoke Hypopen |
| Amgen INC. | $87.78 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Intra-Sana Laboratories | $78.36 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Amarin Pharma, INC. | $49.26 | 2019-2022 | |
| Redhill Biopharma INC. | $47.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $45.67 | 2025 | Zoryve |
| Dexcom, INC. | $42.78 | 2022-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $40.64 | 2025 | Nexletol |
| Abbvie INC. | $39.71 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.19 | 2019-2023 | |
| Genentech USA, INC. | $36.55 | 2020-2022 | |
| Phadia US INC. | $33.38 | 2021-2023 | Immunocap |
| Renalytix Ai, INC. | $22.72 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Paratek Pharmaceuticals, INC. | $18.15 | 2025 | Nuzyra |
| Eyevance Pharmaceuticals LLC | $17.99 | 2021 | |
| Hikma Pharmaceuticals USA | $17.99 | 2021 | |
| Horizon Therapeutics Plc | $16.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.